AI Article Synopsis
- - The study focused on examining the clinical features of hemophilia A (HA) and identifying factors that contribute to the development of factor VIII (FVIII) inhibitors in patients.
- - 113 patients with HA were analyzed, and among those treated with FVIII replacement therapy, 28.24% developed FVIII inhibitors, particularly in severe and moderate cases.
- - Significant factors linked to the development of low-titer FVIII inhibitors included prolonged initial administration of FVIII, the overall health condition of patients, and the use of high doses of FVIII during severe bleeding or major surgeries.
Article Abstract
Objective: To analyze the clinical features of hemophilia A (HA), and the factors associated with the factor VIII (FVIII) inhibitor development.
Methods: One huandred and thirteen patients with HA were recruited in this retrospective study, among whom, 85 were treated with FVIII replacement therapy. The FVIII inhibitor levels and factors associated with the inhibitor development were correspondingly investigated in these 85 patients.
Results: FVIII inhibitor developed in 28.24% of the 85 severe and moderate patients treated with FVIII. Factors of statistical significance (P < 0.05) associated with the low-titer FVIII inhibitor development were as follows: the first enduring adminstration of FVIII, the situation of the patients, and the high dose FVIII used in severe bleeding or major operation.
Conclusion: The development of FVIII inhibitor by Bethesda assay in Chinese hemophilia A patients is not rare, especially that with low-titer. Most of them are severe and moderate patients. The inhibitor development was associated with the following factors: the first adminstration of FVIII for more than 5 days, the severe or moderate conditions of patients, the high dose FVIII used in severe bleeding or major operation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!